Den Europæiske Union - dansk - EMA (European Medicines Agency)

bayer ag - larotrectinib sulfat - abdominal neoplasmer - antineoplastiske midler - vitrakvi som monoterapi er indiceret til behandling af voksne og pædiatriske patienter med solide tumorer, hvor der vises en neurotrophic receptor tyrosin kinase (ntrk) gen fusion,der har en sygdom, der er lokalt avanceret, metastatisk eller hvor kirurgisk resektion er sandsynligvis resultere i alvorlig sygelighed, andwho har ingen tilfredsstillende behandling valg.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastiske midler - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - itraconazol - kapsler - 100 mg